Journal of Clinical Dermatology & Therapy Category: Clinical Type: Research Letter
Gender Bias in Plaque Psoriasis Biologics Studies
- Danvi Bui1*, Jennifer Soung1, Katrina Lee2
- 1 Department Of Clinical Research, Southern California Dermatology, United States
- 2 University Of California Irvine, Irvine, United States
*Corresponding Author:Danvi Bui
Department Of Clinical Research, Southern California Dermatology, United States
Received Date: Jul 17, 2019 Accepted Date: Jul 19, 2019 Published Date: Jul 26, 2019
Recently, multiple biologics have been approved for the treatment of chronic plaque psoriasis. One topic of interest is whether gender influences drug efficacy. Recent studies claim that gender does not affect biologics treatment response in psoriasis patients . However, women are underrepresented in clinical studies that assess the efficacy and safety of new treatments.
a. Each pair of data points represents an individual clinical trial that was included in our analyses. A total of 65 studies were included.
- Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 70: 512-516.
- Wu S, Cho E, Li WQ, Grodstein F, Qureshi AA (2016) Hormonal factors and risk of psoriasis in women: A cohort study. Acta Derm Venereol 96: 927-931.
- van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, et al. (2019) Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol.
Citation:Bui D, Soung J, Lee K (2019) Gender Bias in Plaque Psoriasis Biologics Studies. J Clin Dermatol Ther 5: 034.
Copyright: © 2019 Danvi Bui, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.